

WRITTEN RESOLUTIONS OF

GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENT (IRELAND) (NO.3) LIMITED (the "Company")

We, the undersigned, being the sole member of the Company for the time being entitled to attend and vote at meetings of the Company, HEREBY RESOLVE, in accordance with Section 196 of the Companies Act 2014 and the Constitution of the Company, that the following resolutions be passed by way of written resolution:

1. As a Special Resolution:

"THAT the Company be wound up Voluntarily as a Members' Voluntary Winding Up and that Mr. Michael Jennings and Mr. Brian Murphy of BDO Northern Ireland be and are hereby appointed Joint Liquidators of the Company for the purpose of such winding up".

2. As a Special Resolution:

"THAT the Joint Liquidators be and are hereby authorised, in accordance with Section 618(3) of the Companies Act 2014 and the Memorandum and Articles of Association of the Company, to distribute the whole or part of the assets of the Company amongst the members in specie".

3. As an Ordinary Resolution

"THAT notwithstanding the appointment of the Joint Liquidators, the Directors shall continue to have delegated to them the power to approve and submit all pre-liquidation tax returns of the Company and to sign all relevant documentation in respect thereto together with the power to do all or any ancillary things which may be required of the Company with respect to finalising the Company's pre-liquidation tax affairs."

A copy of the Declaration made by the Directors on 13th December 2021 pursuant to Section 207 of the Companies Act 2014 together with the Report of the Independent Person is appended to this written resolution.



Authorised signatory, Glaxo Group Limited, Corporate Director of GlaxoSmithKline Consumer Healthcare (Overseas) Limited

Date: 22nd December 2021

Time: 3.20 pm



JNI *JAJZS6SP* #246
24/12/2021
COMPANIES HOUSE